Text Size

Blood Pressure Assessment in Atrial Fibrillation

This study is currently recruiting participants.
Verified March 2013 by University of Athens
Sponsor:
Information provided by (Responsible Party):
George S. Stergiou, University of Athens
ClinicalTrials.gov Identifier:
NCT01088269
First received: March 16, 2010
Last updated: March 19, 2013
Last verified: March 2013
History of Changes
  Purpose

This is a cross-sectional study including patients with permanent atrial fibrillation. Assessment will include:

  • clinic blood pressure measurements (mercury sphygmomanometer and automated oscillometric device)
  • 24-hour ambulatory blood pressure monitoring
  • determination of various serum markers and cardiac ultrasound.

Condition
Atrial Fibrillation

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Evaluation of the Oscillometric Blood Pressure Measurement in Atrial Fibrillation and Relation of Blood Pressure With Serum Biomarkers and Echocardiographic Indexes

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Athens:

Primary Outcome Measures:
  • Blood Pressure Measurement in Atrial Fibrillation,Serum Markers and echocardiographic indexes in atrial fibrillation (AF) [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    1. Evaluation of the oscillometric technique of an electronic device in blood pressure measurement.
    2. Evaluation of the relationship of blood pressure levels with serum markers and ultrasonographic cardiac indexes.


Estimated Enrollment: 70
Study Start Date: March 2010
Estimated Study Completion Date: September 2013
Estimated Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
AF
Hypertensive patients in AF
Non-AF
Hypertensive Patients

  Eligibility

Ages Eligible for Study:   25 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

SUBJECTS REFERRED TO HYPERTENSION CENTER

Criteria

Inclusion Criteria:

  • Hypertensives adults in atrial fibrillation

Exclusion Criteria:

  • Renal disease (Cr > 2 mg/l).
  • Patients with pacemaker rhythm during the study.
  • Each patient with acute disease (inflammation, surgery), malignancy, collagen diseases, pulmonary fibrosis, renal failure, liver failure, chronic inflammatory diseases.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01088269

Contacts
Contact: George S Stergiou, MD +302107763117 gstergi@med.uoa.gr

Locations
Greece
Hypertension Center, Third Internal Medicine Dpt, University of Athens Recruiting
Athens, Greece
Contact: George S. Stergiou     00302107763117     gstergi@med.uoa.gr    
Contact: George S. Stergiou, Professor     00302017763117     gstergi@med.uoa.gr    
Sub-Investigator: Antonios Th. Destounis, Phd candidate            
Sponsors and Collaborators
University of Athens
Investigators
Study Chair: George S Stergiou, MD Hypertension Center,Third Department of Medicine,University of Athens,Greece
  More Information

No publications provided

Responsible Party: George S. Stergiou, Associate Professor of Medicine and Hypertension, University of Athens
ClinicalTrials.gov Identifier: NCT01088269     History of Changes
Other Study ID Numbers: BPM IN AF
Study First Received: March 16, 2010
Last Updated: March 19, 2013
Health Authority: Greece: Ethics Committee

Keywords provided by University of Athens:
Blood Pressure Measurement
Atrial Fibrillation
Blood pressure measurement in atrial fibrillation

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on May 16, 2013